Antibacterial-Silica Self-Assembled Medical and Dental Materials

Recurrent dental caries, at the interface between a restoration and tooth, is the reason for over 70% of restorations performed. Despite advances in restorative bonding, caries-causing bacteria will still infiltrate this interface, degrade the bond, and form caries. Current dental restoratives have no effective ability to resist this process by combating these bacteria. The Solution: A new antibacterial dental bonding agent featuring

  • Local delivery of antibacterial precisely where needed
  • Smart antibacterial release in response to bacteria
  • The ability to reduce recurrent caries and restoration failure for 30+ years
  • Compatiblity with current composite restorative systems

and an antibacterial implant abutment that

  • Prevents infection at the implant-gingiva interface without systemic exposure
  • Effective in the days following surgery
  • Integrates with current implant placement procedures
  • Reduces likelihood of costly implant revisions

Growing out of research at the University of Toronto Faculty of Dentistry, Materials Science and Engineering department, and Institute of Biomaterials and Biomedical Engineering, the technology is based on field-leading research in host-biomaterials interactions, infection, and self-assembling materials. The technology utilizes antibacterial-silica (glass) self-assembled materials that respond to the presence of pathogenic bacteria by releasing the drug on demand when bacteria are present. The result is greatly improved patient outcome with no change to practitioner workflow, reducing the likelihood of recurrent caries and implant revisions that may eventually necessitate more complex restorative treatments (root canals and crowns) or total tooth or implant loss.

    Company: Mesosil

     

    ID:

    P1869

    Keywords:

    Biomaterials , Companies , Dentistry , Drug Delivery , Medical Implants and Prosthetics , Nanomaterials and Nanoparticles

    VPRI Contact

    Donna Shukaris

    Commercialization Manager
    Innovations & Partnerships Office (IPO)
    (416) 946-7247

    Related Resources